November's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

India is set to implement new mandatory labelling rules for apparel and home textiles, requiring manufacturers to disclose ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Abbott has agreed to acquire cancer test-maker Exact ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

The U.S. Mint's last pennies struck will be auctioned on Thursday, Dec. 11. Each winning bid gets a 24-karat gold penny along with two 2025 pennies.

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...